Biopharma’s own leaders express a declining sense of industry resilience in the latest wide-reaching survey from Cytiva. The Global Biopharma Resilie...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that the U.S. Federal Bureau of Investigation (FBI) has approved its ForenSeq® Mains...
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ sub...
“This expansion of our relationship with Illumina is a continuation of Illumina Ventures’ strategy to pursue earlier stage investing,” sa...
Prior to joining Catalent, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Tenneco Automotive until it was acquired by A...
U.S. Food and Drug Administration announced a new voluntary pilot program for certain oncology drug products used with certain corresponding in vitro diagn...
Shawn Kumar, Founder and CEO of RhythmScience, expressed his excitement about the partnership, stating, "We are thrilled to partner with MedAxiom, the epit...
Deloitte is proud to announce the launch of "Illustrate Change," a project that seeks to build momentum around representation in medical illustrations and ...
"Compared to adults, children with type 2 diabetes have limited treatment options, even though the disease and symptom onset generally progress more rapidl...
Joining ReMY on the round were new investors Boro Capital, Supernode Ventures, MedMountain Ventures, The Triangle Tweener Fund, David Golan, and Silic...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with canc...
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1...
CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, announced that its CE...
– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 ...
© 2024 Biopharma Boardroom. All Rights Reserved.
